Top Story

Idarubicin dose escalation increases leukemia-free survival in AML

April 26, 2017

Patients with acute myeloid leukemia who received an increased cumulative dose of idarubicin during consolidation therapy demonstrated longer leukemia-free survival without an increase in nonhematologic toxicity than patients who received a standard dose, according to results of a phase 3 study.

“The Australian Leukemia & Lymphoma Group (ALLG) has previously explored the use of high doses of cytarabine during induction therapy,” Kenneth F. Bradstock, MB, PhD, from the Sydney Medical School at the University of Sydney in Australia, and colleagues wrote. “To further improve outcomes in adult AML by anthracycline dose escalation, the ALLG ... [examined] the impact on outcome of an increased idarubicin dose intensity during consolidation therapy after high-dose cytarabine-based induction.”

In the Journals

Topical imiquimod may be effective alternative to surgery for melanoma in situ

April 25, 2017
Topical imiquimod cream may be an effective treatment for patients with melanoma in situ who are not candidates for surgery, according to long-term study outcomes…
In the Journals Plus

ASCO issues recommendations on second-line hormonal therapy for castration-resistant prostate cancer

April 25, 2017
A castrate state should be maintained indefinitely in men who develop castration-resistant prostate cancer despite castrate levels of testosterone, according to a…
FDA News

FDA grants fast track designation to tazemetostat for follicular lymphoma

April 25, 2017
The FDA granted fast track designation to tazemetostat for the treatment of patients with relapsed or refractory follicular lymphoma, according to the drug’s…
In the Journals

Donor age, sex not associated with survival of patients receiving transfusions

April 25, 2017
Survival is not influenced by the age and sex of blood donors among patients receiving blood transfusion, and blood allocation does not need to consider these factors…
More News Headlines »

Individualized Prophylaxis in Hemophilia

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals

This program will provide education for hematologists, nurses, pharmacists, and other healthcare providers involved in…
More »
Meeting News

VIDEO: Gene mutation analysis an ‘important piece’ of melanoma diagnosis

April 3, 2017
More »
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting


Immuno-Oncology Forum: Focus on Non-Small Cell Lung Cancer

This activity is supported by educational grants from Bristol-Myers Squibb; Genentech, Inc.; and Merck & Co., Inc.

Lung cancer accounts for 27% of all cancer deaths in the United States, making it the leading cause of cancer…
More »
Current Issues
View the Current Issue
HemOnc Today